TREM2-SYK signaling controls microglial survival, plaque association, phagocytosis, and disease-associated microglial state transitions. The biology remains strong, but standalone TREM2 agonism in broad early Alzheimer's disease is weakened by recent clinical failure; future use should be stage-specific, biomarker-enriched, or combined with amyloid or tau-directed therapy.
Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase activity, disrupts lysosomal lipid handling, and promotes alpha-synuclein accumulation through a feed-forward lysosomal stress loop. The most actionable therapeutic strategy is GCase restoration or substrate correction in genotype-enriched GBA1-PD rather than broad TFEB activation alone.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
BiomarkerLysosomalneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
2/11
dimensions won
TREM2-SYK microglial activation as a sta
10/11
dimensions won
GBA1/GCase restoration to reduce alpha-s
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.78
0.86
Evidence
0.72
0.86
Novelty
0.50
0.48
Feasibility
0.58
0.82
Impact
0.56
0.84
Druggability
0.74
0.86
Safety
0.42
0.68
Competition
0.40
0.58
Data
0.78
0.86
Reproducible
0.62
0.78
KG Connect
0.50
0.50
Score Breakdown
Dimension
TREM2-SYK microglial activatio
GBA1/GCase restoration to redu
Mechanistic
0.780
0.860
Evidence
0.720
0.860
Novelty
0.500
0.480
Feasibility
0.580
0.820
Impact
0.560
0.840
Druggability
0.740
0.860
Safety
0.420
0.680
Competition
0.400
0.580
Data
0.780
0.860
Reproducible
0.620
0.780
KG Connect
0.500
0.500
Evidence
TREM2-SYK microglial activation as a stage-specific Alzheime
No evidence citations yet
GBA1/GCase restoration to reduce alpha-synuclein pathology i
No evidence citations yet
Debate Excerpts
TREM2-SYK microglial activation as a stage-specifi
4 rounds · quality: 0.76
Persona-Theorist
# Therapeutic Hypotheses in Neurodegeneration
---
## Hypothesis 1: TDP-43 Liquid-Liquid Phase Separation Dysregulation as a Central Mechanism in ALS/FTD
**Mechanism:** TDP-43 undergoes pathological...
Persona-Skeptic
I treat “confidence” here as confidence in the **therapeutic causal hypothesis**, not merely confidence that the pathway is biologically involved.
## 1. TDP-43 LLPS Dysregulation in ALS/FTD
**Weak l...
Persona-Domain Expert
As of April 29, 2026, I would triage these as **2 near-term translational programs**, **3 conditional/retool programs**, and **2 not-ready programs**.
| Rank | Hypothesis | Feasibility | Development ...
Persona-Synthesizer
{"ranked_hypotheses":[{"title":"GBA1/GCase restoration to reduce alpha-synuclein pathology in Parkinson's disease","description":"Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase act...
GBA1/GCase restoration to reduce alpha-synuclein p
4 rounds · quality: 0.76
Persona-Theorist
# Therapeutic Hypotheses in Neurodegeneration
---
## Hypothesis 1: TDP-43 Liquid-Liquid Phase Separation Dysregulation as a Central Mechanism in ALS/FTD
**Mechanism:** TDP-43 undergoes pathological...
Persona-Skeptic
I treat “confidence” here as confidence in the **therapeutic causal hypothesis**, not merely confidence that the pathway is biologically involved.
## 1. TDP-43 LLPS Dysregulation in ALS/FTD
**Weak l...
Persona-Domain Expert
As of April 29, 2026, I would triage these as **2 near-term translational programs**, **3 conditional/retool programs**, and **2 not-ready programs**.
| Rank | Hypothesis | Feasibility | Development ...
Persona-Synthesizer
{"ranked_hypotheses":[{"title":"GBA1/GCase restoration to reduce alpha-synuclein pathology in Parkinson's disease","description":"Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase act...